Table 1.
Significant Differences Between Subject Groups on Th1 and Th2 Type Lymphocyte Subsets
| Lymphocyte Marker | Non-viral (n=62) M (SD) | Viral (n=46) M (SD) | p | d |
|---|---|---|---|---|
| T Cells (CD3+) % pos | 77.46 (7.79) | 79.15 (6.36) | ||
| T Cells (CD3+) / μL | 1606.27 (464.48) | 1749.28 (618.45) | ||
| Natural Killer Cells (CD3-56+) % pos | 6.75 (4.34) | 6.14 (3.58) | ||
| Natural Killer Cells(CD3-56+) cells/μL | 135.24 (90.92) | 133.00 (90.96) | ||
| Natural Killer Cell Cytotoxicity | 9.18 (5.90) ↓ | 9.91 (6.28) ↓ | ||
| T-Helper (CD4+)% pos | 50.66 (7.85) | 56.39 (9.34) ↑ | .001 | -0.666 |
| T-Helper (CD4+ )cells/μL | 1034.27 (361.72) | 1243.67 (459.79) ↑ | .012 | -0.510 |
| T-Cytotoxic (CD3+8+)% pos | 24.51 (6.41) | 20.75 (7.23) | .005 | 0.551 |
| T-Cytotoxic (CD3+8+) cells/μL | 509.34 (196.91) | 465.83 (263.38) | ||
| CD5+ % pos | 75.00 (8.44) | 77.48 (7.08) | ||
| CD5+ cells/μL | 1663.06 (890.47) | 1714.60 (613.71) | ||
| CD5+CD19+ % pos | .79 (.57) ↓ | .84 (1.15) ↓ | ||
| CD5+ CD19+ cells/ μL | 16.47 (12.56) | 17.98 (28.72) | ||
| CD2+ %pos | 82.35 (6.98) | 83.90 (5.51) | ||
| CD2+ cells/μL | 1702.24 (465.87) | 1852.37 (644.16) | ||
| CD2+ CD26+ % pos | 55.36 (12.15) | 60.18 (8.68) ↑ | .024 | -0.463 |
| CD2+ CD26+cells/ μL | 1140.24 (372.95) | 1326.43 (469.89) | .029 | -0.442 |
| CD2+CD4+CD26 + %pos | 41.10 (9.67) | 48.08 (9.40) | .000 | -0.731 |
| CD2+CD4+CD26+ cells/ μL | 846.90 (284.64) | 1068.07 (423.02) | .003 | -0.625 |
| CD4+ CD26+ % pos | 41.24 (9.69) | 48.19 (9.34) | .000 | -0.731 |
| CD4+ CD26+ cells/μL | 849.68 (285.38) | 1070.37 (422.87) | .003 | -0.623 |
| CD2+CD8+CD26+ %pos | 12.07 (4.73) ↑ | 10.49 (4.64) ↑ | ||
| CD2+CD8+CD26+ cells/μL | 249.89 (118.40) | 225.17 (108.77) | ||
| CD8+ %pos | 27.93 (6.42) | 23.81 (7.39) | .003 | 0.595 |
| CD8+ cells/μL | 577.53 (205.08) | 532.80 (290.12) | ||
| CD4+CD45RA+ CD62L- % pos | .59 (.90) | .63 (1.09) | ||
| CD4+CD45RA+ CD62L- cells/μL | 5.97 (8.79) | 7.46 (11.18) | ||
| CD4+CD45RA- CD62L- % pos | 15.80 (6.59) ↑ | 14.08 (5.92) ↑ | ||
| CD4+CD45RA- CD62L- cells/μL | 162.71(86.40) | 169.04 (85.52) | ||
| CD8+ CD45RA- CD62L- % pos | 24.79 (10.06) ↑ | 20.37 (8.25) ↑ | .016 | 0.482 |
| CD8+ CD45RA-CD62L- cells/ μL | 150.76 (122.22) | 108.65 (70.62) | .039 | 0.422 |
| CD8+ CD45RA+CD62L- % pos | 16.68 (9.23) ↑ | 18.65 (11.67) ↑ | ||
| CD8+ CD45RA+CD62L-cells/μL | 150.76 (122.22) | 108.65 (70.62) | ||
| CD4/CD8 Ratio | 1.81 | 2.36 | ||
| B cells (CD19+) % pos | 14.53 (6.40) | 13.50 (5.34) | ||
| B cells (CD19+) cells/μL | 313.81 (191.83) | 284.22 (114.40) | ||
| CD4+CD45RA + CD62L+ % pos | 24.19 (14.82) | 29.71 (17.40) ↑ | ||
| CD4+CD45RA + CD62L+ cells/μL | 253.46 (184.24) | 386.00 (321.53) | .015 | -0.524 |
| CD4+CD45RA- CD62L+ % pos | 59.42 (13.18) ↑ | 55.58 (16.80) ↑ | ||
| CD4+CD45RA- CD62L+ cells/μL | 628.12 (273.97) ↑ | 681.04 (304.60) ↑ | ||
| CD8+CD45RA-CD62L+ % pos | 21.17 (8.80) ↑ | 20.25 (11.66) ↑ | ||
| CD8+CD45RA-CD62L+cells/μL | 118.48 (56.36) | 106.38 (85.10) | ||
| CD8+CD45RA+CD62L+ % pos | 37.34 (15.07) ↑ | 40.73 (14.87) ↑ | ||
| CD8+ CD45RA+CD62L+ cells/μL | 212.58 (120.07) | 211.86 (140.20) |